GSK releases 2030 epidemiological projections for key health conditions
GSK has published a comprehensive data set projecting patient populations across major global markets through 2030 to inform medical planning.
GSK has released an epidemiological report providing projections for patient populations across several critical therapeutic areas, including infectious diseases, respiratory conditions, and oncology. The data covers prevalence estimates for key markets, specifically the US, the EU5, China, and Japan, with forecasts extending to 2030.
The report breaks down figures by specific demographic cohorts and diagnosis stages, covering conditions ranging from shingles and RSV to chronic conditions like asthma, COPD, and systemic lupus erythematosus. It provides detailed metrics on diagnosed and treated patient numbers to illustrate the scale of medical demand.
These projections are intended to assist in identifying the scope of future healthcare requirements. By outlining patient prevalence and eligibility trends in these regions, the data serves as a framework for assessing long-term medical strategy and resource deployment across the company's core portfolios.